Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...
Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose (HD) version of the ...
The biotech's growth portfolio continues to add to its overall top line.
Investor's Business Daily on MSN
Biogen had a nearly perfect sales sweep, but one beat really stood out
Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.
(RTTNews) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies. Through the ...
UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...
Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results